CAXTON ASSOCIATES LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.

Quarter-by-quarter ownership
CAXTON ASSOCIATES LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$497,807
+15.8%
13,035
+33.3%
0.08%
+78.6%
Q2 2022$430,000
-3.8%
9,782
-6.6%
0.04%
+35.5%
Q4 2020$447,000
-66.1%
10,471
-78.7%
0.03%
-73.0%
Q2 2020$1,319,000
+129.8%
49,216
+52.1%
0.12%
+45.6%
Q4 2019$574,00032,3480.08%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders